According to filings with the U.S. Securities and Exchange Commission, Yatiri Bio is raising up to $7,000,000.00 in new funding. Sources indicate that as part of senior management Chief Executive Officer, Pilgrim Jackson played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Yatiri Bio
Proteomics is the large-scale study of the proteome, which consists of all the proteins produced in an organism, cell, or biological system. Using high-resolution mass spectrometry, data from the proteome can provide insight into proteins and their signaling pathways as the drivers of human physiology and disease. Yatiri Bio explicitly prioritizes this data as the key to understanding how and why particular drugs successfully eradicate disease. Recent advances in this technology allow for the identification and quantification of thousands (>8,000) of proteins per sample. In addition, the signaling pathways can be accurately monitored via analysis of post-translational modifications (PTM) that steer biochemical responses. Consequently, these analyses address the relevant disease on a cellular level including direct observation of the effects of drug perturbation. The advantage of studying the proteome (versus the current standard of identifying only a selective few biomarkers) is that we are able to identify more robust biomarker signatures, improve patient selection, and drive pathway-based therapies for personalized medicine.

To learn more about Yatiri Bio, visit http://yatiribio.com/

Contact:
Pilgrim Jackson, Chief Executive Officer
831-325-4481
https://www.linkedin.com/in/pilgrimjackson/

SOURCE: http://www.intelligence360.io
Copyright (c) 2024 SI360 Inc. All rights reserved.